246 related articles for article (PubMed ID: 37953617)
21. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
22. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
23. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
24. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
26. Guidance for peptide vaccines for the treatment of cancer.
Yamaguchi Y; Yamaue H; Okusaka T; Okuno K; Suzuki H; Fujioka T; Otsu A; Ohashi Y; Shimazawa R; Nishio K; Furuse J; Minami H; Tsunoda T; Hayashi Y; Nakamura Y;
Cancer Sci; 2014 Jul; 105(7):924-31. PubMed ID: 25040224
[TBL] [Abstract][Full Text] [Related]
27. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
29. Tumor vaccination using messenger RNA: prospects of a future therapy.
Kreiter S; Diken M; Selmi A; Türeci Ö; Sahin U
Curr Opin Immunol; 2011 Jun; 23(3):399-406. PubMed ID: 21497074
[TBL] [Abstract][Full Text] [Related]
30. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Lorentzen CL; Haanen JB; Met Ö; Svane IM
Lancet Oncol; 2022 Oct; 23(10):e450-e458. PubMed ID: 36174631
[TBL] [Abstract][Full Text] [Related]
31. Cancer vaccines: translation from mice to human clinical trials.
Maeng H; Terabe M; Berzofsky JA
Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
[TBL] [Abstract][Full Text] [Related]
32. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
Anderson RJ; Schneider J
Vaccine; 2007 Sep; 25 Suppl 2():B24-34. PubMed ID: 17698262
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
36. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials.
Turriziani M; Fantini M; Benvenuto M; Izzi V; Masuelli L; Sacchetti P; Modesti A; Bei R
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):265-96. PubMed ID: 22630596
[TBL] [Abstract][Full Text] [Related]
37. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy.
White RL; Amin A
Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
[TBL] [Abstract][Full Text] [Related]
39. Preclinical and clinical development of DNA vaccines for prostate cancer.
Colluru VT; Johnson LE; Olson BM; McNeel DG
Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642
[TBL] [Abstract][Full Text] [Related]
40. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
Vermaelen K
Front Immunol; 2019; 10():8. PubMed ID: 30723469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
